Human anti-CD40 antibody and poly IC:LC adjuvant combination induces potent T cell responses in the lung of nonhuman primates

Journal of Immunology

Volumn 195, Issue 3, 2015, Pages 1015-1024

  Thompson, Elizabeth A ^a,b   Liang, Frank ^a,b   Lindgren, Gustaf ^a   Sandgren, Kerrie J ^a   Quinn, Kylie M ^b   Darrah, Patricia A ^b   Koup, Richard A ^b   Seder, Robert A ^b   Kedl, Ross M ^c   Loré, Karin ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CD103 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CD69 ANTIGEN; CD70 ANTIGEN; ENVELOPE PROTEIN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; TUMOR NECROSIS FACTOR; ANTIBODY; CARBOXYMETHYLCELLULOSE; IMMUNOLOGICAL ADJUVANT; POLYINOSINIC POLYCYTIDYLIC ACID; POLYLYSINE; VACCINE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL TRACKING; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG POTENCY; DRUG POTENTIATION; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LUNG LAVAGE; MOLECULAR DYNAMICS; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RHESUS MONKEY; TIME SERIES ANALYSIS; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; BRONCHOALVEOLAR LAVAGE FLUID; CELL DIFFERENTIATION; CYTOLOGY; IMMUNOLOGY; LUNG; LYMPHOCYTE ACTIVATION; RESPIRATORY TRACT MUCOSA; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; ANTIGENS, CD40; BRONCHOALVEOLAR LAVAGE FLUID; CARBOXYMETHYLCELLULOSE SODIUM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; DENDRITIC CELLS; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-12; LUNG; LYMPHOCYTE ACTIVATION; MACACA MULATTA; POLY I-C; POLYLYSINE; RESPIRATORY MUCOSA; VACCINATION; VACCINES;

EID: 84937723618     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1500078     Document Type: Article

References (49)

1. Hanyu, K., T. Iida, H. Shiba, T. Ohashi, Y. Eto, and K. Yanaga. 2008. Immunogene therapy by adenovirus vector expressing CD40 ligand for metastatic liver cancer in rats. Anticancer Res. 28(5A): 2785-2789.
2. van Kooten, C., and J. Banchereau. 2000. CD40-CD40 ligand. J. Leukoc. Biol. 67: 2-17.
3. Buhlmann, J. E., T. M. Foy, A. Aruffo, K. M. Crassi, J. A. Ledbetter, W. R. Green, J. C. Xu, L. D. Shultz, D. Roopesian, R. A. Flavell, et al. 1995. In the absence of a CD40 signal, B cells are tolerogenic. Immunity 2: 645-653.
4. Diehl, L., A. T. Den Boer, E. I. van der Voort, C. J. Melief, R. Offringa, and R. E. Toes. 2000. The role of CD40 in peripheral T cell tolerance and immunity. J. Mol. Med. 78: 363-371.
5. Davis, I. D., Q. Chen, L. Morris, J. Quirk, M. Stanley, M. L. Tavarnesi, P. Parente, T. Cavicchiolo, W. Hopkins, H. Jackson, et al. 2006. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients. J. Immunother. 29: 499-511.
6. Gladue, R. P., T. Paradis, S. H. Cole, C. Donovan, R. Nelson, R. Alpert, J. Gardner, E. Natoli, E. Elliott, R. Shepard, and V. Bedian. 2011. The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice. Cancer Immunol. Immunother. 60: 1009-1017.
7. Ahonen, C. L., C. L. Doxsee, S. M. McGurran, T. R. Riter, W. F. Wade, R. J. Barth, J. P. Vasilakos, R. J. Noelle, and R. M. Kedl. 2004. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J. Exp. Med. 199: 775-784.
8. McWilliams, J. A., P. J. Sanchez, C. Haluszczak, L. Gapin, and R. M. Kedl. 2010. Multiple innate signaling pathways cooperate with CD40 to induce potent, CD70-dependent cellular immunity. Vaccine 28: 1468-1476.
9. Sanchez, P. J., J. A. McWilliams, C. Haluszczak, H. Yagita, and R. M. Kedl. 2007. Combined TLR/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in vivo. J. Immunol. 178: 1564-1572.
10. Barrios, K., and E. Celis. 2012. TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers. Cancer Immunol. Immunother. 61: 1307-1317.
11. Hailemichael, Y., Z. Dai, N. Jaffarzad, Y. Ye, M. A. Medina, X. F. Huang, S. M. Dorta-Estremera, N. R. Greeley, G. Nitti, W. Peng, et al. 2013. Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion. Nat. Med. 19: 465-472.
12. Assudani, D., H. I. Cho, N. DeVito, N. Bradley, and E. Celis. 2008. In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. Cancer Res. 68: 9892-9899.
13. Advani, R., A. Forero-Torres, R. R. Furman, J. D. Rosenblatt, A. Younes, H. Ren, K. Harrop, N. Whiting, and J. G. Drachman. 2009. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J. Clin. Oncol. 27: 4371-4377.
14. Furman, R. R., A. Forero-Torres, A. Shustov, and J. G. Drachman. 2010. A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk. Lymphoma 51: 228-235.
15. Beatty, G. L., D. A. Torigian, E. G. Chiorean, B. Saboury, A. Brothers, A. Alavi, A. B. Troxel, W. Sun, U. R. Teitelbaum, R. H. Vonderheide, and P. J. O'Dwyer. 2013. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res. 19: 6286-6295.
16. Vonderheide, R. H., J. M. Burg, R. Mick, J. A. Trosko, D. Li, M. N. Shaik, A. W. Tolcher, and O. Hamid. 2013. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. OncoImmunology 2: e23033.
17. Vonderheide, R. H., K. T. Flaherty, M. Khalil, M. S. Stumacher, D. L. Bajor, N. A. Hutnick, P. Sullivan, J. J. Mahany, M. Gallagher, A. Kramer, et al. 2007. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 25: 876-883.
18. Takahashi, N., T. Miura, Y. Kitagawa, and A. Matsushima, inventors; Kyowa Hakka Kirin Co., Ltd., assignee. Anti-cd40 antibody mutants. United States patent application 14/017,789, Publication No. US 2014/0105907 A1. 2014 Apr 17.
19. Byrd, J. C., T. J. Kipps, I. W. Flinn, M. Cooper, O. Odenike, J. Bendiske, J. Rediske, S. Bilic, J. Dey, J. Baeck, and S. O'Brien. 2012. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk. Lymphoma 53: 2136-2142.
20. Park, H., L. Adamson, T. Ha, K. Mullen, S. I. Hagen, A. Nogueron, A. W. Sylwester, M. K. Axthelm, A. Legasse, M. Piatak, Jr., et al. 2013. Polyinosinic-polycytidylic acid is the most effective TLR adjuvant for SIV Gag protein-induced T cell responses in nonhuman primates. J. Immunol. 190: 4103-4115.
21. Wille-Reece, U., B. J. Flynn, K. Loré, R. A. Koup, R. M. Kedl, J. J. Mattapallil, W. R. Weiss, M. Roederer, and R. A. Seder. 2005. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc. Natl. Acad. Sci. USA 102: 15190-15194.
22. Wille-Reece, U., B. J. Flynn, K. Loré, R. A. Koup, A. P. Miles, A. Saul, R. M. Kedl, J. J. Mattapallil, W. R. Weiss, M. Roederer, and R. A. Seder. 2006. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J. Exp. Med. 203: 1249-1258.
23. Quinn, K. M., A. Da Costa, A. Yamamoto, D. Berry, R.W. Lindsay, P. A. Darrah, L. Wang, C. Cheng, W. P. Kong, J. G. Gall, et al. 2013. Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J. Immunol. 190: 2720-2735.
24. Loré, K., A. Sönnerborg, A. L. Spetz, U. Andersson, and J. Andersson. 1998. Immunocytochemical detection of cytokines and chemokines in Langerhans cells and in vitro derived dendritic cells. J. Immunol. Methods 214: 97-111.
25. Bullock, T. N., and H. Yagita. 2005. Induction of CD70 on dendritic cells through CD40 or TLR stimulation contributes to the development of CD8+ T cell responses in the absence of CD4+ T cells. J. Immunol. 174: 710-717.
26. Keller, A. M., A. Schildknecht, Y. Xiao, M. van den Broek, and J. Borst. 2008. Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8+ T cell tolerance and permits effective immunity. Immunity 29: 934-946.
27. Dong, H., N. A. Franklin, D. J. Roberts, H. Yagita, M. J. Glennie, and T. N. Bullock. 2012. CD27 stimulation promotes the frequency of IL-7 receptorexpressing memory precursors and prevents IL-12-mediated loss of CD8(+) T cell memory in the absence of CD4(+) T cell help. J. Immunol. 188: 3829-3838.
28. Kurche, J. S., C. Haluszczak, J. A. McWilliams, P. J. Sanchez, and R. M. Kedl. 2012. Type I IFN-dependent T cell activation is mediated by IFN-dependent dendritic cell OX40 ligand expression and is independent of T cell IFNR expression. J. Immunol. 188: 585-593.
29. Nehete, P. N., B. P. Nehete, L. Hill, P. R. Manuri, V. Baladandayuthapani, L. Feng, J. Simmons, and K. J. Sastry. 2008. Selective induction of cell-mediated immunity and protection of rhesus macaques from chronic SHIV(KU2) infection by prophylactic vaccination with a conserved HIV-1 envelope peptide-cocktail. Virology 370: 130-141.
30. Nehete, P. N., B. P. Nehete, P. Manuri, L. Hill, J. L. Palmer, and K. J. Sastry. 2005. Protection by dendritic cells-based HIV synthetic peptide cocktail vaccine: preclinical studies in the SHIV-rhesus model. Vaccine 23: 2154-2159.
31. Koopman, G., N. Beenhakker, I. Nieuwenhuis, G. Doxiadis, P. Mooij, J. W. Drijfhout, J. Koestler, T. Hanke, Z. Fagrouch, E. J. Verschoor, et al. 2013. DNA/long peptide vaccination against conserved regions of SIV induces partial protection against SIVmac251 challenge. AIDS 27: 2841-2851.
32. Rosario, M., A. Bridgeman, E. D. Quakkelaar, M. F. Quigley, B. J. Hill, M. L. Knudsen, V. Ammendola, K. Ljungberg, N. Borthwick, E. J. Im, et al. 2010. Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur. J. Immunol. 40: 1973-1984.
33. Darrah, P. A., D. T. Patel, P. M. De Luca, R. W. B. Lindsay, D. F. Davey, B. J. Flynn, S. T. Hoff, P. Andersen, S. G. Reed, S. L. Morris, et al. 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13: 843-850.
34. Betts, M. R., M. C. Nason, S. M. West, S. C. De Rosa, S. A. Migueles, J. Abraham, M. M. Lederman, J. M. Benito, P. A. Goepfert, M. Connors, et al. 2006. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. 107: 4781-4789.
35. Seder, R. A., P. A. Darrah, and M. Roederer. 2008. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8: 247-258.
36. Richman, L. P., and R. H. Vonderheide. 2014. Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer. Cancer Immunol. Res. 2: 19-26.
37. Vonderheide, R. H., and M. J. Glennie. 2013. Agonistic CD40 antibodies and cancer therapy. Clin. Cancer Res. 19: 1035-1043.
38. Nimmerjahn, F., and J. V. Ravetch. 2005. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310: 1510-1512.
39. Rüter, J., S. J. Antonia, H. A. Burris, R. D. Huhn, and R. H. Vonderheide. 2010. Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol. Ther. 10: 983-993.
40. Carpenter, E. L., R. Mick, J. Rüter, and R. H. Vonderheide. 2009. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation. J. Transl. Med. 7: 93.
41. Januszkiewicz, A., K. Loré, P. Essén, B. Andersson, M. A. McNurlan, P. J. Garlick, O. Ringdén, J. Andersson, and J. Wernerman. 2002. Response of in vivo protein synthesis in T lymphocytes and leucocytes to an endotoxin challenge in healthy volunteers. Clin. Exp. Immunol. 130: 263-270.
42. Kamphuis, E., T. Junt, Z. Waibler, R. Forster, and U. Kalinke. 2006. Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 108: 3253-3261.
43. Gunzer, M., H. Riemann, Y. Basoglu, A. Hillmer, C. Weishaupt, S. Balkow, B. Benninghoff, B. Ernst, M. Steinert, T. Scholzen, et al. 2005. Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion. Blood 106: 2424-2432.
44. Fanger, N. A., C. Liu, P. M. Guyre, K. Wardwell, J. O'Neil, T. L. Guo, T. P. Christian, S. P. Mudzinski, and E. J. Gosselin. 1997. Activation of human T cells by major histocompatability complex class II expressing neutrophils: proliferation in the presence of superantigen, but not tetanus toxoid. Blood 89: 4128-4135.
45. Reinisch, W., W. Tillinger, C. Lichtenberger, A. Gangl, M. Willheim, O. Scheiner, and G. Steger. 1996. In vivo induction of HLA-DR on human neutrophils in patients treated with interferon-gamma. Blood 87: 3068.
46. Beauvillain, C., Y. Delneste, M. Scotet, A. Peres, H. Gascan, P. Guermonprez, V. Barnaba, and P. Jeannin. 2007. Neutrophils efficiently cross-prime naive T cells in vivo. Blood 110: 2965-2973.
47. Lee, S., K. L. Stokes, M. G. Currier, K. Sakamoto, N. W. Lukacs, E. Celis, and M. L. Moore. 2012. Vaccine-elicited CD8+ T cells protect against respiratory syncytial virus strain A2-line19F-induced pathogenesis in BALB/c mice. J. Virol. 86: 13016-13024.
48. Mikhak, Z., J. P. Strassner, and A. D. Luster. 2013. Lung dendritic cells imprint T cell lung homing and promote lung immunity through the chemokine receptor CCR4. J. Exp. Med. 210: 1855-1869.
49. Farber, D. L., N. A. Yudanin, and N. P. Restifo. 2014. Human memory T cells: generation, compartmentalization and homeostasis. Nat. Rev. Immunol. 14: 24-35.